Literature DB >> 19564843

Papillary hyperplasia of the gallbladder in pancreaticobiliary maljunction represents a senescence-related lesion induced by lysolecithin.

Junpei Yamaguchi1, Motoko Sasaki, Kenichi Harada, Yoh Zen, Yasunori Sato, Hiroko Ikeda, Keita Itatsu, Yukihiro Yokoyama, Hisami Ando, Tetsuo Ohta, Akio Kubota, Koichi Shimizu, Yuji Nimura, Masato Nagino, Yasuni Nakanuma.   

Abstract

Cellular senescence, an irreversible growth arrest, is considered to play as safeguard against malignant progression, though such a mechanism is speculative in human carcinogenesis. In gallbladder carcinoma, cholecystolithiasis and pancreaticobiliary maljunction (PBM) are major risk factors. Here, by using 113 surgically resected gallbladders and cultures of human gallbladder epithelial cells (HGECs) and gallbladder carcinoma cell line (TGBC2TKB), we examined carcinogenesis with respect to cellular senescence. Among 15 cases of PBM in which carcinoma was found in 4 cases, nonneoplastic gallbladder mucosa showed diffuse papillary hyperplasia (PHP). PHP was not found in gallbladders with cholecystolithiasis. Interestingly, PHP exhibited senescent features such as expression of p16(INK4A) and low cell proliferative activity. In contrast, EZH2, a polycomb group protein, was overexpressed in intraepithelial neoplasm and carcinoma in gallbladders with cholecystolithiasis. In PBM, EZH2 was expressed only in carcinoma foci but not in PHP. Cultured HGECs treated with lysolecithin, the level of which is elevated in gallbladder bile of PBM, showed increased expression of p16(INK4A) and senescence-associated beta-galactosidase. Conversely, enforced overexpression of EZH2 in senescent HGECs reduced p16(INK4A) expression. A knockdown of EZH2 in cultured TGBC2TKB cells increased p16(INK4a) expression. In conclusion, PHP in PBM may act as a barrier to malignant transformation for decades. EZH2 may be responsible for the escape from cellular senescence followed by malignant transformation in the gallbladder of PBM.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19564843     DOI: 10.1038/labinvest.2009.65

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  7 in total

1.  Primary papillary hyperplasia of the gallbladder mimicking gallbladder cancer.

Authors:  Hiroyuki Baba; Mai Wakabayashi; Atsushi Oba; Takashi Tsubomoto; Hiroshi Nakamura; Takahiro Sanada; Hiroshi Kuwabara; Kazumi Nakajima; Narihide Goseki
Journal:  Int Surg       Date:  2014 May-Jun

Review 2.  Epithelial cell senescence: an adaptive response to pre-carcinogenic stresses?

Authors:  Corinne Abbadie; Olivier Pluquet; Albin Pourtier
Journal:  Cell Mol Life Sci       Date:  2017-07-13       Impact factor: 9.261

3.  Enhancer of Zeste Homolog 2 (EZH2) in Malignant Progression of Gallbladder Carcinoma.

Authors:  Gayatri Behera; Suvradeep Mitra; Tushar S Mishra; Suvendu Purkait
Journal:  J Gastrointest Cancer       Date:  2020-10-14

4.  An immunohistochemical panel of insulin-like growth factor II mRNA-binding protein 3 (IMP3), enhancer of zeste homolog 2 (EZH2), and p53 is useful for a diagnosis in bile duct biopsy.

Authors:  Motoko Sasaki; Yasunori Sato
Journal:  Virchows Arch       Date:  2021-06-11       Impact factor: 4.064

Review 5.  Precursor Lesions of Gallbladder Carcinoma: Disease Concept, Pathology, and Genetics.

Authors:  Yuki Fukumura; Lu Rong; Yifare Maimaitiaili; Toshio Fujisawa; Hiroyuki Isayama; Jun Nakahodo; Masataka Kikuyama; Takashi Yao
Journal:  Diagnostics (Basel)       Date:  2022-01-28

6.  Senescent fibroblasts enhance early skin carcinogenic events via a paracrine MMP-PAR-1 axis.

Authors:  Nicolas Malaquin; Chantal Vercamer; Fatima Bouali; Sébastien Martien; Emeric Deruy; Nicolas Wernert; Maggy Chwastyniak; Florence Pinet; Corinne Abbadie; Albin Pourtier
Journal:  PLoS One       Date:  2013-05-10       Impact factor: 3.240

Review 7.  Long Non-Coding RNAs in Biliary Tract Cancer-An Up-to-Date Review.

Authors:  Dino Bekric; Daniel Neureiter; Markus Ritter; Martin Jakab; Martin Gaisberger; Martin Pichler; Tobias Kiesslich; Christian Mayr
Journal:  J Clin Med       Date:  2020-04-22       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.